



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

CHMP feedback to working parties

Presented by: Fátima Ventura (CHMP)
25 September 2019

An agency of the European Union






Summary (September 2018 – September 2019)

- CHMP opinions
 - New medicines
 - Community Reviews
 - PRIME eligibility (September 2018 – July 2019)
- HCP/Patients input provided in the context of CHMP activities



Positive opinion – September 2018 – September 2019





Positive opinion – September 2018 – September 2019

Haematology

| Name | Active S | Indication |
|--------------------------|----------------|--|
| Ondexxya (Feb/19) | andexanet alfa | Treatment of direct factor Xa(FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding |



EC



Rx

Press release: First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban

| Name | Active S | Indication |
|--------------------------|--|--|
| Zynteglo (Mar/19) | autologous CD34+ cells encoding β A-T87Q-globin gene | Treatment of transfusion-dependent β -thalassaemia |



EC



Rx

Press release: New gene therapy to treat rare inherited blood condition

Advanced Therapy





Positive opinion – September 2018 – September 2019

Haematology

| Name | Active S | Indication |
|--------------------------|--------------------------|---|
| Esperoct (Apr/19) | turoctocog alfa pegol | Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency) |



EC



Rx



Cancer

| Name | Active S | Indication |
|--------------------------|---------------|--|
| Vitrakvi (Jul/19) | larotrectinib | Treatment of patients with solid tumours that display a neurotrophic tyrosine receptor kinase (NTRK) gene fusion |



EC

Rx



Press release: First “histology-independent” treatment for solid tumours with a specific gene mutation – Innovative design – basket trial



Positive opinion – September 2018 – September 2019

Vaccine

| Name | Active S | Indication |
|---------------------------|---|--|
| Dengvaxia (Oct/19) | dengue tetravalent vaccine (live, attenuated) | For the prevention of dengue caused by dengue virus serotypes 1, 2, 3 and 4 in people who are between 9 and 45 years old, live in an endemic area and already had a prior dengue virus infection |

EC



Press release: First vaccine for prevention of dengue



Positive opinion – September 2018 – September 2019

Metabolism

| Name | Active S | Indication |
|--------------------------|------------|------------------------------|
| Palynziq (Feb/19) | pegvaliase | Treatment of phenylketonuria |



EC



Rx



Press release: CHMP recommends authorisation of new treatment for phenylketonuria, a rare inherited metabolic disease

| Name | Active S | Indication |
|--------------------------|--------------|---|
| Waylivra (Feb/19) | volanesorsen | Treatment of familial chylomicronaemia syndrome |



EC



Rx

Press release: First treatment for rare disease characterised by high levels of triglycerides in blood



Positive opinion – September 2018 – September 2019

Neurology

| Name | Active S | Indication |
|--------------------------|--------------|-------------------------|
| Emgality (Sep/18) | galcanezumab | Prophylaxis of migraine |

EC



Rx



Press release: New medicine for the prevention of migraine

| Name | Active S | Indication |
|--------------------------|----------------|--|
| Namuscla (Oct/18) | mexiletine hcl | Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders |



EC

Press release: First treatment for rare inherited muscle contraction disorders



Positive opinion – September 2018 – September 2019

Neurology

| Name | Active S | Indication |
|-----------------------|---------------|---|
| Sixmo (Apr/19) | buprenorphine | substitution treatment for opioid drug dependence |

EC



Rx



Implant

| Name | Active S | Indication |
|---------------------------|-------------|--|
| Epidyolex (Jul/19) | cannabidiol | Treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome |



EC





Positive opinion – September 2018 – September 2019

Infectious Diseases

| Name | Active S | Indication |
|-------------------------|-----------|---|
| Dectova (Feb/19) | zanamivir | Treatment of complicated and potentially life-threatening influenza |



EC



Ophthalmology

| Name | Active S | Indication |
|--------------------------|-----------------------|--|
| Luxturna (Sep/18) | voretigene neparvovec | Treatment of retinal dystrophies caused by RPE65 mutations |



EC



Rx



Press release: New gene therapy for rare inherited disorder causing vision loss recommended for approval



Positive opinion – September 2018 – September 2019

Other areas

| Name | Active S | Indication |
|---|--------------|---|
| Fexinidazole Winthrop (Nov/18) | fexinidazole | Treatment of human African trypanosomiasis (HAT) due to <i>Trypanosoma brucei gambiense</i> |

Art. 58/WHO



Press release: CHMP recommends first oral-only treatment for sleeping sickness



Negative opinions – September 2018 – September 2019

Neurology

| Name | Active S | Indication |
|-------------------------|------------|--|
| Exondys (Set/18) | eteplirsen | Treatment of Duchenne muscular dystrophy |



EC

Cancer

| Name | Active S | Indication |
|----------------------------------|-------------|------------------------------|
| Cabazitaxel Teva (Apr/19) | cabazitaxel | Treatment of prostate cancer |

EC



Community reviews (Art. 31) Sep2018 – Sep 2019)

| | Object | Scope |
|---|--|---|
| Sep/18 (Start Jul/18) | Sartan medicines (Angiotensin-II-receptor antagonists) | Started with Valsartan – extended to other “Sartans” - Review of impurities (N-Nitrosodimethylamine (NDMA)) |
| Dec/2018 (Start) | Fosfomicin -containing medicinal products (Antibiotics) | DE - Significant differences between Member States - reappraisal of the role of fosfomicin in the context of increasing resistance to antibiotics |
| Dec/2018 (opinion) | Metamizole -containing medicinal products (analgesic) | PL - Substantial differences between Member States - aligning doses and use during pregnancy and breastfeeding |
| Dec/2018 (opinion)/Mar/2019 (opinion re-exam) | Omega-3 fatty acid medicines | SE – Efficacy - not effective in preventing further heart problems after a heart attack |
| Jan/2019 | Direct oral anticoagulants Eliquis (apixaban), Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban) | Reviewing the results of a study - risk of major bleedings vs other anticoagulants |



Community reviews (Art. 31/20) Sep 2018 – Sep 2019)

| | Object | Scope |
|--------------------|--|---|
| Apr/19 | Lartruvo (olaratumab) with doxorubicin | Results of the ANNOUNCE study (SO- CMA) - not better than monotherapy with doxorubicin in increase survival of patients with soft tissue cancer – MA revocation |
| May/2019 (Start) | Methocarbamol and paracetamol -containing medicines (analgesic) | DE – assessment of B/R due to lack of efficacy - short-term, symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders, and potential interactions between active ingredients |
| Jun/2019 (opinion) | Bacterial lysates -containing medicinal products indicated for respiratory conditions | IT - should only be used for the prevention of recurrent respiratory infections, with the exception of pneumonia - no robust data on efficacy at treating existing respiratory infections, or prevention of pneumonia |
| Sept/2019 (start) | Ranitidine -containing medicinal products | B/R due to concerns on preliminary results showing the presence of N-Nitrosodimethylamine (NDMA) in some batches and preliminary findings that NDMA could be generated under certain conditions in vivo |



PRIME eligibility

| Name | Substance type | Therapeutic area | Therapeutic indication | Data of eligibility granted |
|---|------------------|---------------------|--|-----------------------------|
| Lonafarnib | Chemical | Infectious Diseases | Treatment of hepatitis D virus infection | Dec/2018 |
| Anti-respiratory syncytial virus human IgG1k monoclonal antibody (MEDI889) | Biological | Infectious diseases | Prevention of lower respiratory tract infection caused by respiratory syncytial virus | Jan/2019 |
| Purified Inactivated Zika Virus vaccine (TAK-426) | Immunological | Vaccines | Active immunization for the prevention of disease caused by Zika virus | Mar/2019 |
| Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528) | Advanced therapy | Oncology | Treatment of adult patients with relapsed or refractory multiple myeloma, whose prior regimens included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody and who had disease progression on the last regime | Mar/2019 |
| Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (KB103) | Advanced therapy | Dermatology | Treatment of Dystrophic Epidermolysis Bullosa | Mar/2019 |



PRIME eligibility

| Name | Substance type | Therapeutic area | Therapeutic indication | Data of eligibility granted |
|--|------------------|------------------|--|-----------------------------|
| Allogeneic EBV-specific Cytotoxic T Lymphocyte | Advanced Therapy | Oncology | Treatment of rituximab refractory Post-Transplant Lymphoproliferative Disorder (PTLD) | May/2019 |
| Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA(QR-110) | Chemical | Ophthalmology | Treatment of Leber's congenital amaurosis due to the p.Cys998X mutation in the CEP290 Gene | Jul/2019 |



Interaction between CHMP and HCP - Participation in Scientific Advisory Groups and ad-hoc Experts Groups – Jan – Sept 2019

➤ Contributing for decision on recommendations

| Name | Product | Indication |
|------------|--------------------------------------|--|
| 25/01/2019 | Hemlibra | Hemophilia A |
| 07/02/2019 | Evenity | Osteoporosis |
| 12/02/2019 | Bacterial lysates as Anti-infectives | Art. 31 - no robust data on efficacy at treating existing respiratory infections, or prevention of pneumonia |
| 18/03/2019 | Vitrakvi | Abdominal Neoplasms |
| 19/03/2019 | Omega 3 | Art. 31 - not effective in preventing further heart problems after a heart attack |
| 15/04/2019 | Radicava (edaravone) | Amyotrophic lateral sclerosis (ALS) |
| 20/05/2019 | Doxolipad | Pegylated liposomal Doxorubicin - Breast and Ovarian Neoplasms – BE issues |
| 20/06/2019 | Epidyolex | Lennox Gastaut Syndrome Epilepsies, Myoclonic |
| 06/09/2019 | Zolgensma | SMA Type I |



Interaction between CHMP and HCP – reviewed of safety

communications – Jan – Sept 2019 = Total 13

| Name | Product | Indication/Scope |
|------------|--|--|
| 31/01/2019 | Sartans - PHC | Nitrosamines impurities |
| 08/04/2019 | Prevention of medication errors for Trisenox | Leukemia, Promyelocytic, Acute |
| 25/04/2019 | Lartruvo – PHC | Art. 20 - Results of the ANNOUNCE study (SO- CMA) - not better than monotherapy with doxorubicin in increase survival of patients with soft tissue cancer – revokation of MA |
| 29/04/2019 | Tyverb - PHC | Breast Neoplasms |
| 26/06/2019 | Bacterial lysate medicines - PHC | Art. 31 - no robust data on efficacy at treating existing respiratory infections, or prevention of pneumonia |
| 26/07/2019 | Methotrexate dosing errors | Inflammatory conditions, methotrexate just once a week. |



Interaction between CHMP and Patient's representatives - Participation in CHMP plenary sessions – Since Jan 2019

➤ Contributing for decision on recommendations

| | CHMP Activity | Indication |
|--|-------------------------|---|
| 35 patients' rep | Every SAG | Various |
| 50 responses / 11 different countries | First Written procedure | Ongoing – product and condition not to be disclosed |
| 3 patient's rep | OE (Jan, Apr, Jun) | Various |



OBRI GADO



fatima.ventura@infarmed.pt